Pro and contra IBR-eradication.
Bovine herpesvirus type 1 (BoHV-1) is the causative agent of respiratory and genital tract infections such as infectious rhinotracheitis (IBR), infectious pustular vulvovaginitis (IPV, balanoposthitis (IBP), and abortion. Despite of a pronounced immune response, the virus is never eliminated from an infected host but establishes life-long latency and may be reactivated at intervals. Europe has a long history of fighting against BoHV-1 infections, yet, only a small number of countries has achieved IBR-eradication. Therefore, it seemed appropriate to review the reasoning pro and contra such a task. Clearly, the goal can indeed be achieved as has been demonstrated by a number of European countries. However, detection and stamping out of seemingly healthy virus carriers is inevitable in the process. Unfortunately, the use of vaccines is only of temporary and limited value. Therefore, there are numerous considerations to be put forward against such plans, including the high costs, the great risks, and the unsatisfactory quality of tools. If either control or eradication of IBR is nonetheless a goal, then better vaccines are needed as well as better companion tests. Moreover, better tools for the characterization of viral isolates are required. Collaborative actions to gather viral strains from as many countries as possible for inclusion into a newly created clustering library would be most advantageous.
Ackermann
Mathias
M
Institute of Virology, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 266a, CH-8057 Zurich, Switzerland.
Engels
Monika
M
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D006566:Herpesviridae Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D007242:Herpesvirus 1, Bovine; D022283:Herpesvirus Vaccines / Q000191:economics / Q000276:immunology; D007241:Infectious Bovine Rhinotracheitis / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D022581:Vaccines, Marker; D014775:Virus Activation; D017735:Virus Latency
D022283:Herpesvirus Vaccines; D022581:Vaccines, Marker